PolyNovo reports first patient treated in US

Company News

PolyNovo (ASX:PNV) has announced the first US patient has been treated with its Biodegradable Temporising Matrix (BTM).

This patient’s complex trauma injury left the forearm and dorsal (upper) aspect of the hand de-gloved, said the company. "This exposes the tendons, like in free flap surgery, risking loss of function in the hand. The BTM should ensure full function of the hand once healed."

It continued, "Our sales team worked closely with the surgical team. The surgeon’s feedback was that the BTM was significantly easier to handle and apply than other Matrix products she had previously used. Further cases are scheduled."

According to CEO Paul Brennan, "It is significant that the first case is a complex trauma injury. The trauma, reconstructive and surgical wound market is the largest opportunity for our BTM. We have previously demonstrated the BTM’s effectiveness in covering tendons and bone. We see this as an exciting start to our future US success.”